Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on October 30, 2023. The report discloses a material corporate event occurring on the same date. Note: The input metadata references "Onkure Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Reneo Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The primary financial data relates to a specific capital transaction:
- Transaction Type: Common Stock Repurchase
- Shares Repurchased: 576,443 shares
- Aggregate Purchase Price: Approximately $4.4 million
- Price Per Share: $7.64
- Counterparty: vTv Therapeutics LLC (Selling Stockholder)
- Transaction Structure: Private, non-underwritten transaction
Material Changes
The filing reports a reduction in the company's outstanding common stock and a corresponding cash outflow of approximately $4.4 million. This transaction represents a direct repurchase from a specific selling stockholder rather than an open market buyback. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies beyond the disclosure of the repurchase agreement itself. The document is limited to reporting the execution of the transaction under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the impact of the $4.4 million cash outflow on the company's current liquidity position.
- Confirm the updated number of outstanding shares following the cancellation of the 576,443 repurchased shares.
- Review the relationship between Reneo Pharmaceuticals and vTv Therapeutics LLC to understand the context of the private sale.
- Check subsequent filings for any additional stock repurchases or changes in capital structure.